Anti-tRNA synthetase inflammatory myopathy antibodies
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Anti-tRNA synthetase inflammatory myopathy antibodies. Severe weakness, Arthritis, Association with cancer. Fully referenced neurology checklist.
Anti-Jo1 (histidyl): features
- Severe weakness
- Arthritis
- Association with cancer
- Responsive to Rituximab
Anti-OJ (isoleucyl): features
Locked: subscribe to see this section.
Anti-PL7 (threonyl): features
Locked: subscribe to see this section.
Anti-PL12 (alanyl): features
Locked: subscribe to see this section.
Other anti-tRNA synthetase antibodies
Locked: subscribe to see this section.
References
- Rietveld A, Lim J, de Visser M, et al. Autoantibody testing in idiopathic inflammatory myopathies. Pract Neurol 2019; pii: practneurol-2017-001742 (Epub ahead of print).
- Stuhlmüller B, Schneider U, González-González JB, Feist E. Disease specific autoantibodies in idiopathic inflammatory myopathies. Front Neurol 2019; 10:438.
- Yamasaki Y, Yamada H, Nozaki T, et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum 2006; 54:2004-2009.
- Matsushita T, Hasegawa M, Fujimoto M, et al. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. J Rheumatol 2007; 34:1012-1018.
